GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: BIIB
Buy $440
up 21.00 %

Biogen Idec Inc (NASDAQ: BIIB) reiterated to Buy with price target $440 by Argus

Monday,  Feb 2, 2015  1:25 PM ET by Kristen Bailey

Here is more proof that the Argus rating can guide you in smart investing. Argus reiterated Biogen Idec Inc (NASDAQ: BIIB) to Buy with price target
$440 with today's price of $386.15. Argus rated Biogen Idec Inc (NASDAQ: BIIB) to Buy with price target $360 on 01/30/2014, when the price was $319.59. Biogen Idec Inc's stock price gained 21% since then.
By following the previous Argus's recommendation on BIIB, you would have gained 21% in 368 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research. Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company's prospects as an investment in terms of value, expected growth and risks. Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm's underwriting business. Because we're not a broker/dealer, we don't have "inventory" of a stock that we have to move with a tainted recommendation. We have developed a six-point system for analyzing the stocks in our Universe of Coverage. We believe that this system



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy